November 8, 2023 03:45 PM ESTUpdated 04:36 PM
Pharma
FDA+
Marketing

FDA watch­dog ad­mon­ish­es Evofem for mar­ket­ing brochure for its con­tra­cep­tive Phexxi

Beth Snyder Bulik

Senior Editor

Evofem Bio­sciences last week re­ceived an un­ti­tled let­ter from the FDA, which cit­ed “mis­lead­ing” ben­e­fits in a mar­ket­ing brochure for its …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times